Latest

Low-Dose Naltrexone Is Not a Rescue Medication: Setting Realistic Expectations for a Regulatory and Modulatory Therapy

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Introduction Low-dose naltrexone (LDN) has gained increasing recognition as a valuable tool in integrative and functional medicine, particularly for chronic inflammatory, autoimmune, and neuroimmune conditions. However, as clinical interest in LDN has grown, so

By Yoon Hang Kim MD
Evaluating Surgical and Integrative Oncology Options in Early-Stage Breast Carcinoma with Favorable Histology and Multiple Lesions

Integrative Oncology

Evaluating Surgical and Integrative Oncology Options in Early-Stage Breast Carcinoma with Favorable Histology and Multiple Lesions

A Case-Based Review of Attributable Benefit, Attributable Risk, and the Role of Integrative Strategies Alongside Definitive Treatment Yoon Hang Kim, MD, MPH  •  Board-Certified in Preventive Medicine  |  Integrative & Functional Medicine Physician Introduction When a client presents with a new diagnosis of early-stage breast carcinoma, two sets of

By Yoon Hang Kim MD
Low-Dose Naltrexone and Prolactin:What Clinicians Should Know About an Emerging Question

LDN Prolactin

Low-Dose Naltrexone and Prolactin:What Clinicians Should Know About an Emerging Question

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com Introduction As low-dose naltrexone (LDN) prescribing grows across integrative, functional, and conventional medicine settings, clinicians are occasionally encountering an unexpected laboratory finding: a mildly elevated serum prolactin in a client taking

By Yoon Hang Kim MD